Clinical Trial Update: Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age [Phase 2]

View source ↗

Summary

Phase 2 clinical trial protocol repurposing empagliflozin for Duchenne muscular dystrophy–associated dilated cardiomyopathy in children aged 6-18; currently not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy
• Duchenne Muscular Dystrophy

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Sebastiano Lava | Conditions: DMD-associated Dilated Cardiomyopathy | Phase 2 | Status: NOT_YET_RECRUITING